Transgene's Mpox Vaccine Candidate Shows Strong Preclinical Results
Event summary
- Transgene presented preclinical data at WCID 2026 showing its TG-MVA™ vaccine candidate provides robust protection against mpox, with efficacy and safety comparable to approved reference vaccines.
- TG-MVA™ demonstrated strong survival rates in mice (100%) and primates (87%), along with comparable immune responses and safety profiles.
- The vaccine uses a scalable cell line manufacturing process, addressing global supply gaps for mpox and smallpox vaccines.
- Transgene plans to advance TG-MVA™ rapidly into clinical development while maintaining focus on its myvac® platform.
The big picture
Transgene's TG-MVA™ vaccine candidate addresses critical gaps in the mpox and smallpox vaccine supply chain, leveraging scalable manufacturing technology initially developed for its myvac® platform. The preclinical results position Transgene as a potential new supplier in a market dominated by a limited number of manufacturers, highlighting the company’s strategic pivot toward infectious disease prevention alongside its core focus on cancer immunotherapies.
What we're watching
- Clinical Development Pace
- The pace at which Transgene advances TG-MVA™ into clinical trials will determine its competitive positioning in the mpox and smallpox vaccine market.
- Regulatory Approval Pathway
- Whether TG-MVA™ can secure regulatory approvals quickly, leveraging its comparable efficacy data to approved vaccines.
- Manufacturing Scalability
- How effectively Transgene scales up production using its innovative cell line-based manufacturing process to meet global demand.
Related topics